What Is Stromal Vascular Fraction

Stromal vascular fraction (SVF) is a concentrated mixture of cells isolated from a person's own adipose (fat) tissue through enzymatic digestion or mechanical disruption. The resulting cell pellet contains mesenchymal stem cells, endothelial progenitor cells, pericytes, macrophages, T-regulatory cells, and fibroblasts, all suspended together in a form that can be injected back into the body. Because the cells come from the patient's own tissue, SVF is classified as an autologous therapy.

Adipose tissue is the most accessible and abundant reservoir of adult mesenchymal stem cells in the human body, containing roughly 500 times more stem cells per gram than bone marrow. This density makes fat a practical source for regenerative applications without the morbidity of a bone marrow biopsy. The diversity of cell types within SVF is itself significant: rather than delivering a single purified cell line, SVF provides an ecosystem of progenitor and support cells that interact through paracrine signaling, secreting cytokines, growth factors, and extracellular vesicles that collectively modulate inflammation, stimulate angiogenesis, and recruit endogenous repair mechanisms.

From a longevity perspective, SVF sits at the intersection of several aging hallmarks. Stem cell exhaustion, one of the recognized hallmarks of aging, describes the progressive decline in the regenerative capacity of tissue-resident stem cells. By reintroducing a concentrated bolus of these progenitor cells and their supporting cast, SVF therapy aims to partially restore the tissue repair signaling that degrades with age. Additionally, the immunomodulatory properties of the T-regulatory cells and M2-polarized macrophages within SVF may help counteract inflammaging, the chronic low-grade inflammation that accompanies biological aging.

The process begins with a small-volume liposuction, typically collecting 50 to 200 milliliters of subcutaneous fat from the abdomen, flanks, or thighs under tumescent local anesthesia. The harvested fat is then processed to separate the cellular components from the lipid-laden mature adipocytes and extracellular matrix. Enzymatic processing uses collagenase to digest the connective tissue scaffold, freeing the embedded cells; mechanical methods rely on physical agitation, emulsification, or centrifugation to achieve the same separation without enzymes. After filtration and centrifugation, a cell pellet forms at the bottom of the processing vessel. This pellet is the SVF.

Once isolated, SVF exerts its effects primarily through paracrine signaling rather than direct engraftment and differentiation. The mesenchymal stem cells within SVF secrete a broad array of bioactive molecules: vascular endothelial growth factor (VEGF) promotes new blood vessel formation, hepatocyte growth factor (HGF) supports tissue remodeling, and transforming growth factor beta (TGF-beta) modulates fibrosis and immune responses. Exosomes and microvesicles released by these cells carry mRNA and microRNA cargo that can reprogram gene expression in neighboring cells. Meanwhile, T-regulatory cells dampen excessive immune activation, and endothelial progenitor cells contribute to vascular repair.

The net biological effect depends heavily on the local microenvironment into which SVF is injected. In an inflamed joint, the immunomodulatory signals predominate, reducing cartilage-degrading enzyme activity and promoting chondrocyte survival. In ischemic or damaged tissue, the angiogenic and trophic factors take center stage. This context-dependent behavior is sometimes described as the cells "reading" and responding to local distress signals, which is why SVF has been explored across a wide range of indications despite containing the same starting material.

The orthopedic application of SVF, particularly for knee osteoarthritis, has the largest body of clinical evidence. Multiple randomized controlled trials and systematic reviews have compared SVF injection to hyaluronic acid or corticosteroid injections, generally showing improvements in pain scores and functional outcomes at six to eighteen month follow-ups. However, trial sizes remain modest (typically 30 to 100 participants), follow-up periods rarely exceed two years, and blinding is difficult because of the liposuction component. Some trials report structural cartilage improvements on MRI, though the magnitude and consistency of these findings vary across studies.

For non-orthopedic applications, the evidence is considerably thinner. Small case series and pilot studies have explored SVF for Crohn's disease fistulas, chronic wounds, scleroderma, erectile dysfunction, and cosmetic volume restoration. Preclinical animal data supports anti-inflammatory and pro-angiogenic effects in models of ischemia, autoimmune disease, and neurodegeneration, but translation to human outcomes remains incomplete. The longevity-specific use of systemic SVF infusion is supported primarily by mechanistic reasoning and animal lifespan studies rather than human clinical trials. Regulatory variability across countries complicates the research landscape: some jurisdictions allow point-of-care SVF use, while others classify it as an unapproved biologic, limiting the ability to conduct large-scale trials.

The liposuction harvest carries standard surgical risks including infection, bruising, hematoma, and, rarely, fat embolism. Enzymatic processing with collagenase introduces a theoretical concern about residual enzyme activity if washing is incomplete, though clinical reports of adverse events from this are scarce. Because SVF is autologous, immune rejection and graft-versus-host reactions do not apply; however, injecting a heterogeneous cell population into a joint or tissue carries a small risk of heterotopic ossification or unintended tissue formation if the cells encounter atypical differentiation signals. The regulatory status of SVF varies by country and by processing method, so patients should verify that any clinic offering SVF therapy is operating within its legal framework and using validated processing protocols. Cost is substantial, as SVF procedures are not covered by insurance in most markets, and repeat treatments may be recommended.